Promising early results for Lutonix US IDE trial in obstructed AV fistulae


The first US randomised controlled trial for drug-coated balloon use for arteriovenous fistula obstructions for 50 years, the Lutonix (Bard) IDE trial was a talking point of the 2017 LINC meeting (24–27 January, Leipzig, Germany). Scott Trerotola, who presented eight-month data from the trial, explained to Vascular News why this trial is so significant and how it could change treatment approaches.